nach oben

Clinical Rheumatology

Erschienen in:

01.05.2010 | Original Article

Antibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis

verfasst von: Andrea Tesija-Kuna, Simeon Grazio, Marijana Miler, Ines Vukasovic, Porin Peric, Nada Vrkic

Erschienen in: Clinical Rheumatology | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Antibodies against mutated citrullinated vimentin (anti-MCV) are of a comparable diagnostic value in rheumatoid arthritis (RA) as antibodies targeting citrullinated peptides (anti-CCP). Anti-CCP are present in up to 15% of psoriatic arthritis (PsA) patients, while the prevalence of anti-MCV in PsA patients has been poorly investigated. The aim of the present study was to assess the prevalence and relevance of anti-MCV antibodies in PsA patients. The study included 56 PsA patients. Clinical features, disease activity, and functional ability were noted by an experienced rheumatologist. Serum samples of all patients were analyzed for anti-MCV and anti-CCP antibodies using enzyme-linked immunosorbent assay. Data on 92 patients with RA, 44 patients with other inflammatory rheumatic diseases, and 107 healthy controls from a previous study were used to compare the prevalence of anti-MCV antibodies in PsA patients. Anti-MCV antibodies were positive in only two out of 56 (3.6%) PsA patients, which was significantly lower compared to RA patients (63%). The anti-MCV level was moderately positive and borderline in one patient each. Both patients had asymmetric polyarthritis, dactylitis, moderate to high disease activity, and were anti-CCP and rheumatoid factor (RF) negative. There was no significant difference in anti-MCV levels according to clinical subtypes of PsA and no correlation of anti-MCV levels with anti-CCP, RF, disease activity variables, and functional ability indices. According to study results, anti-MCV antibodies can be detected in a very small proportion of PsA patients with polyarthritic disease and are primarily related to the polyarthritic pattern rather than the specific diagnosis of RA.

Gladman DD, Antoni C, Mease P, Clegg DO, Nash P (2005) Psoriatic arthritis and psoriasis: classification, clinical features, pathophysiology, immunology, genetics. Ann Rheum Dis 64(Suppl):14–17

Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK (1987) Psoriatic arthritis—an analysis of 220 patients. Q J Med 62:127–141PubMed

Torre-Alonso JC, Rodrigues-Perez A, Arribas-Castrillom JM, Ballina Garcia J, Riestra Noriega JL, Lopez Larrea C (1991) Psoriatic arthritis (PA): a clinical immunologic and radiological study. Brit J Rheumatol 30:245–250CrossRef

McHugh NJ, Balachrishnan C, Jones SM (2003) Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology Oxford 42:778–783CrossRefPubMed

Riedmann JP, Munoz S, Kavanaugh A (2005) The use of second generation anti-CCP antibody (anti-CCP2) testing in rheumatoid arthritis—a systematic review. Clin Exp Rheumatol 23(Suppl. 39):S69–S76

Rönnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L, van Vollenhoven RF (2005) Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 64:1744–1749CrossRefPubMed

Van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BAW, Breedveld FC, Verweij CL et al (2004) Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis. Arthritis Rheum 50:709–715CrossRefPubMed

Nijenhuis S, Zendman AJ, Vossenaar ER, Pruijn GJ, van Venrooij WJ (2004) Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specific marker. Clin Chim Acta 350:17–34CrossRefPubMed

Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C, Senshu T, Serre G (2001) The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol 166(6):4177–4184PubMed

10.

Chang X, Yamada R, Suzuki A, Kochi Y, Sawada T, Yamamoto K (2005) Citrullination of fibronectin in rheumatoid arthritis synovial tissue. Rheumatology 44(11):1374–1382CrossRefPubMed

11.

Suzuki A, Yamad R, Ohtake-Yamanaka M, Okazaki Y, Sawada T, Yamamoto K (2005) Anti-citrullinated collagen type I antibody is a target of autoimmunity in rheumatoid arthritis. Biochem Biophys res Commun 333:418–426CrossRefPubMed

12.

Kinloch A, Tatzer V, Wait R, Peston D, Lundberg K, Donatien P et al (2005) Identification of citrullinated α-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 7:R1421–R1429CrossRefPubMed

13.

Vossenaar ER, Despres N, Lapointe E, van der Heijden A, Lora M, Senshu T et al (2004) Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 6(2):R142–R150CrossRefPubMed

14.

Strelkov SV, Herrmann H, Aebi U (2003) Molecular architecture of intermediate filaments. Bioassays 25:243–251CrossRef

15.

Bang H, Egerer K, Gauliard A, Lϋthke K, Rudolph PE, Fredenhagen G et al (2007) Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 56(8):2503–2511CrossRefPubMed

16.

Dejaco C, Klotz W, Larcher H, Duftner C, Schirmer M, Herold M (2006) Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther 8(4):R119CrossRefPubMed

17.

Soos L, Szekanecz Z, Szabo Z, Fekete A, Zeher M, Horvath IF et al (2007) Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. J Rheumatol 34:1658–1663PubMed

18.

Mathsson L, Mullazehi M, Wick MC, Sjöberg O, van Vollenhoven R, Klareskog L, Rönnelid J (2008) Antibodies against citrullinated vimentin in rheumatoid arthritis. Higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 58:36–45CrossRefPubMed

19.

Poulsom H, Charles PJ (2008) Antibodies to citrullinated vimentin are a specific and sensitive marker for the diagnosis of rheumatoid arthritis. Clinic Rev Allerg Immunol 34:4–10CrossRef

20.

Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C et al (1995) American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38:727–735CrossRefPubMed

21.

Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, Landewé R, van der Tempel H, Mielantset H et al (2003) Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 62:127–132CrossRefPubMed

22.

Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48CrossRefPubMed

23.

Blackmore M, Gladman DD, Husted J, Long J, Farewell VT (1995) Measuring health status in psoriatic arthritis: the health assessment questionnaire and its modification. J Rheumatol 22:886–893PubMed

24.

Marks R, Barton SP, Shuttleworth D, Finlay AY (1989) Assessment of disease progress in psoriasis. Arch Dermatol 125:235–240CrossRefPubMed

25.

Fredriksson T, Pettersson U (1978) Severe psoriasis: oral therapy with a new retinoid. Dermatologica 157:238–244CrossRefPubMed

26.

Webster K, Cella D, Yost K (2003) The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 16:79CrossRef

27.

Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J (2005) Validation of the functional assessment of chronic illness therapy fatigue scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 32:811–819PubMed

28.

Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA et al (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48:35–45CrossRefPubMed

29.

Vossenar ER, Radstake TR, van der Heijden A, van Mansum MA, Dieteren C, de Rooij DJ et al (2004) Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis 63:373–381CrossRef

30.

Brickmann K, Yazdani-Biuki BJ, Mϋller T, Graninger WB, Brezinschek HP (2006) Anti-mutated-citrullinated-vimentin antibodies (MCV) in psoriatic arthritis. (Abstract) Ann Rheum Dis 65(Suppl II):648

31.

Fabien N, Olson NO, Goetz J, Johanet C, Escande A, Bardin N et al (2008) Prevalence of autoantibodies to cyclic citrullinated peptide in patients with rheumatic diseases other than rheumatoid arthritis: a French multicenter study. Clinic Rev Allerg Immunol 34:40–44CrossRef

32.

Alenius GM, Berglin E, Rantapää-Dahlqvist S (2006) Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation. Ann Rheum Dis 65:398–400CrossRefPubMed

33.

Inanc N, Dalkilic E, Kamali S, Kasapoglu-Günal E, Elbir Y, Direskeneli H, Inanc M (2007) Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol 26:17–23CrossRefPubMed

34.

Bogliolo L, Alpini C, Caporali R, Scirè CA, Moratti R, Montecucco C (2005) Antibodies to cyclic citrullinated peptides in psoriatic arthritis. J Rheumatol 32:511–515PubMed

35.

Cruyssen BV, Hoffman IEA, Zmierczak H, Van den Berghe M, Kruithof E, De Rycke L et al (2005) Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis 64:1145–1149CrossRef

36.

McHugh NJ, Balachrishnan C, Jones SM (2003) Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology 42:778–783CrossRefPubMed

37.

Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H et al (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741–2749CrossRefPubMed

38.

Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH et al (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50:380–386CrossRefPubMed

39.

Innala L, Kokkonen H, Eriksson C, Jiddell E, Berglin E, Rantapaa-Dahlqvist S (2008) Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol 35:1–7

40.

Kastbom A, Strandberg G, Lindroos A, Skogh T (2004) Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 63:1085–1089CrossRefPubMed

41.

Mikuls TR, O’Dell JR, Stoner JA, Parrish LA, Arend WP, Norris JM, Holers VM (2004) Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum 50:3776–3782CrossRefPubMed

42.

Caramaschi P, Biasi D, Tonolli E, Pieropan S, Martinelli N, Carletto A et al (2005) Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment. Rheumatol Int 26:58–62CrossRefPubMed

43.

Braun-Moscovici Y, Markovits D, Zinder O, Schapira D, Rozin A, Ehrenburg M et al (2006) Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-α therapy in patients with rheumatoid arthritis. J Rheumatol 33:497–500PubMed

44.

Chen HA, Lin KC, Chen CH, Liao HT, Wang HP, Chang HN et al (2006) The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 65:35–39CrossRefPubMed

45.

Alessandri C, Bombardieri M, Pap N, Cinquini M, Magrini L, Tincani A, Valesini G (2004) Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNF alpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 63:1218–1221CrossRefPubMed

Titel: Antibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis
verfasst von: Andrea Tesija-Kuna
Simeon Grazio
Marijana Miler
Ines Vukasovic
Porin Peric
Nada Vrkic
Publikationsdatum: 01.05.2010
Verlag: Springer-Verlag
Erschienen in: Clinical Rheumatology / Ausgabe 5/2010
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-009-1345-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Intervallfasten zur Regeneration des Herzmuskels?

14.05.2024 Herzinfarkt Nachrichten

Die Nahrungsaufnahme auf wenige Stunden am Tag zu beschränken, hat möglicherweise einen günstigen Einfluss auf die Prognose nach akutem ST-Hebungsinfarkt. Darauf deutet eine Studie an der Uniklinik in Halle an der Saale hin.

Klimaschutz beginnt bei der Wahl des Inhalators

14.05.2024 Klimawandel Podcast

Auch kleine Entscheidungen im Alltag einer Praxis können einen großen Beitrag zum Klimaschutz leisten. Die neue Leitlinie zur "klimabewussten Verordnung von Inhalativa" geht mit gutem Beispiel voran, denn der Wechsel vom klimaschädlichen Dosieraerosol zum Pulverinhalator spart viele Tonnen CO₂. Leitlinienautor PD Dr. Guido Schmiemann erklärt, warum nicht nur die Umwelt, sondern auch Patientinnen und Patienten davon profitieren.

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2010

Sickness certification for musculoskeletal conditions

Assessment of the effectiveness of low-level laser therapy on the hands of patients with rheumatoid arthritis: a randomized double-blind controlled trial

Osteoarthritis: can anti-cytokine therapy play a role in treatment?

A systematic review of homoeopathy for the treatment of fibromyalgia

Clinical analysis of primary Sjögren’s syndrome complicating anemia